These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1919 related articles for article (PubMed ID: 26654227)

  • 21. Treatment of aggressive non-Hodgkin's lymphoma: a north American perspective.
    Sehn LH; Connors JM
    Oncology (Williston Park); 2005 Apr; 19(4 Suppl 1):26-34. PubMed ID: 15934515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 1. current treatment approaches.
    Hernandez-Ilizaliturri FJ; Czuczman MS
    Oncology (Williston Park); 2009 May; 23(6):546-53. PubMed ID: 19544696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
    Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
    J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.
    Jacobsen ED; Sharman JP; Oki Y; Advani RH; Winter JN; Bello CM; Spitzer G; Palanca-Wessels MC; Kennedy DA; Levine P; Yang J; Bartlett NL
    Blood; 2015 Feb; 125(9):1394-402. PubMed ID: 25573987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Advances in the Molecular Diagnosis and Therapy of Relapsed/Refractory Diffuse Large B-cell Lymphoma -Review].
    Wang Y; Xia B; Zhang YZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):603-608. PubMed ID: 29665940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel disease targets and management approaches for diffuse large B-cell lymphoma.
    Wilson WH; Hernandez-Ilizaliturri FJ; Dunleavy K; Little RF; O'Connor OA
    Leuk Lymphoma; 2010 Aug; 51 Suppl 1(Suppl 1):1-10. PubMed ID: 20658952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diffuse Large B-cell lymphoma: Prognostic markers and their impact on therapy.
    Jamil MO; Mehta A
    Expert Rev Hematol; 2016 May; 9(5):471-7. PubMed ID: 26808217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TAK1 is a druggable kinase for diffuse large B-cell lymphoma.
    Wu Y; Yang R; Ming Y; Xu Y; Chen H; Yao M; Chen X; Mao R; Fan Y
    Cell Biochem Funct; 2019 Apr; 37(3):153-160. PubMed ID: 30907011
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Specific Lipid and Metabolic Profiles of R-CHOP-Resistant Diffuse Large B-Cell Lymphoma Elucidated by Matrix-Assisted Laser Desorption Ionization Mass Spectrometry Imaging and in Vivo Imaging.
    Barré FPY; Claes BSR; Dewez F; Peutz-Kootstra C; Munch-Petersen HF; Grønbæk K; Lund AH; Heeren RMA; Côme C; Cillero-Pastor B
    Anal Chem; 2018 Dec; 90(24):14198-14206. PubMed ID: 30422637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lenalidomide combined with R-GDP in a patient with refractory CD5-positive diffuse large B-cell lymphoma: A promising response and review.
    Zhang Y; Wang X; Liu Y; Sun C; Shi W; Huang H
    Cancer Biol Ther; 2018 Jul; 19(7):549-553. PubMed ID: 29611764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients.
    Di M; Huntington SF; Olszewski AJ
    Oncologist; 2021 Feb; 26(2):120-132. PubMed ID: 33230948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bone Marrow Molecular Markers Associated with Relapsed/Refractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma.
    Wang D; Liu P; Zhang Y; Liu HY; Shen D; Che YQ
    Biomed Res Int; 2018; 2018():1042597. PubMed ID: 30534553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?
    Amin AD; Peters TL; Li L; Rajan SS; Choudhari R; Puvvada SD; Schatz JH
    Cold Spring Harb Mol Case Stud; 2017 May; 3(3):a001719. PubMed ID: 28487884
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.
    Yazbeck V; Shafer D; Perkins EB; Coppola D; Sokol L; Richards KL; Shea T; Ruan J; Parekh S; Strair R; Flowers C; Morgan D; Kmieciak M; Bose P; Kimball A; Badros AZ; Baz R; Lin HY; Zhao X; Reich RR; Tombes MB; Shrader E; Sankala H; Roberts JD; Sullivan D; Grant S; Holkova B
    Clin Lymphoma Myeloma Leuk; 2018 Sep; 18(9):569-575.e1. PubMed ID: 30122201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dysregulated MDR1 by PRDM1/Blimp1 Is Involved in the Doxorubicin Resistance of Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
    Qing K; Jin Z; Xu Z; Wang W; Li X; Zhang Y; Wang L; Zhu H; Xiang R; Wu S; Li R; Jiang G; Xue K; Li J
    Chemotherapy; 2022; 67(1):12-23. PubMed ID: 34844236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular Subtyping in Diffuse Large B Cell Lymphoma: Closer to an Approach of Precision Therapy.
    Karmali R; Gordon LI
    Curr Treat Options Oncol; 2017 Feb; 18(2):11. PubMed ID: 28229364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathologically complete remission to combination of invariant NK T cells and anti-CD20 antibody in a refractory HIV+ diffuse large B-cell lymphoma patient.
    Wang J; Zhang R; Ding X; Jin Y; Qin R; Xia B; Liao Q; Hu H; Song W; Wang Z; Zhang X; Xu J
    Immunotherapy; 2022 Jun; 14(8):599-607. PubMed ID: 35443802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tissue microarray in a subset of South African patients with DLBCL.
    Sissolak G; Wood L; Smith L; Chan JW; Armitage J; Jacobs P
    Transfus Apher Sci; 2013 Oct; 49(2):120-32. PubMed ID: 23942329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted treatment and new agents in diffuse large B-cell lymphoma.
    Leonard JP; Martin P; Barrientos J; Elstrom R
    Semin Hematol; 2008 Jul; 45(3 Suppl 2):S11-6. PubMed ID: 18760704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 96.